Polo-like kinase 1 inhibition in KRAS-mutated metastatic colorectal cancer

Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-24-0251. Online ahead of print.ABSTRACTInhibition of Polo-like kinase 1 (Plk1) is a promising new target and therapeutic strategy in metastatic colorectal cancer, especially those with KRAS mutations. New data support further development of onvansertib, and highlights the role of circulating tumor DNA in phase 1 clinical trials.PMID:38470499 | DOI:10.1158/1078-0432.CCR-24-0251
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research